Spectral Medical Inc.
TSX:EDT.TOMedical - Diagnostics & Research
-$0.02 today
- Market cap
- $306.00M
- Beta
- 0.23
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.13
Volume 0.02M
Average 0.06M
EDT.TO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Spectral Medical Inc.TSX: EDT.TO
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of CA$891K rose 55.8% year over year, ahead of the +26.1% change in trailing-twelve-month revenue. Sequentially, it rose 133.2% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of CA$2.16M (-11.7%) for the fiscal year ending Dec 2026, a slowdown from the +6.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$891K+133.2% QoQ
- Last fiscal yearDec 2025
- CA$2.44M+6.8% YoY
- LTMMar 2026
- CA$2.76M+26.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +55.8% | -25.7% | -81.5 pp |
| 1 year | +6.8% | -11.7% | -18.5 pp |
| 3-year CAGR | +13.6% | +168.4% | +154.8 pp |
| 5-year CAGR | +141.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
CAD · from the income statement
- Latest · FY2025
- 2.44M CAD
- Year-over-year change
- +6.8%
- 4-year CAGR
- +5.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.44M | +6.8% |
| FY2024 | 2024-12-31 | 2.29M | +43.1% |
| FY2023 | 2023-12-31 | 1.6M | -4.1% |
| FY2022 | 2022-12-31 | 1.67M | -16.5% |
| FY2021 | 2021-12-31 | 2M | — |
Revenue vs competitors
How EDT.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +26.1% is the 4th highest of 7, against a peer median of +27.3%.
- Over three fiscal years its annual growth of +13.6% compares with a peer median of +35.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | CA$318.43M CAD | -7.2% | +11.2% | |
| LTM Mar 2026 | CA$310.92M CAD | +15.6% | -5.1% | |
| LTM Mar 2026 | CA$66.52M CAD | +25.7% | +38.6% | |
| LTM Mar 2026 | $51.17M USD | +65.5% | +207.5% | |
| LTM Mar 2026 | $50.92M USD | +28.9% | +35.4% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $18.76M USD | +64.7% | +34.8% |
| LTM Mar 2026 | CA$2.76M CAD | +26.1% | +13.6% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding EDT.TO) | — | +27.3% | +35.1% | |
Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2M | 1.67M | 1.6M | 2.29M | 2.44M |
| Cost of Revenue | 832K | 684K | 936K | 1.27M | 7.6M |
| Gross Profit | 1.16M | 983K | 662K | 1.02M | (5.16M) |
| Gross Margin | 58.3% | 59.0% | 41.4% | 44.5% | -211.1% |
| Research & Development | 0 | 0 | 4.68M | 3.97M | 4.33M |
| Selling, General & Admin | 7.01M | 8.64M | 11.29M | 11.62M | 11.73M |
| Operating Expenses | 7.86M | 9.43M | 12.08M | 13.02M | 6.53M |
| Depreciation & Amortization | 294K | 272K | 218K | 251K | 250K |
| EBITDA | (6.38M) | (7.18M) | (13.96M) | (11.97M) | (11.44M) |
| EBITDA Margin | -319.4% | -430.7% | -873.3% | -523.5% | -468.3% |
| Operating Income | (6.66M) | (8.45M) | (11.42M) | (12M) | (11.69M) |
| Operating Margin | -333.5% | -506.7% | -714.7% | -524.8% | -478.5% |
| Interest Income | 0 | 0 | 0 | 0 | 5.39M |
| Interest Expense | 28K | 176K | 1.33M | 3.18M | 5.16M |
| Other Income / Expenses | (40K) | 819K | (4.09M) | (3.4M) | (36M) |
| Income Before Tax | (6.96M) | (7.63M) | (15.51M) | (15.4M) | (47.69M) |
| Pre-Tax Margin | -348.6% | -457.6% | -970.4% | -673.4% | -1952.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.79M) | (11.28M) | (15.66M) | (15.4M) | (47.69M) |
| Net Margin | -440.1% | -676.7% | -980.1% | -673.8% | -1953.0% |
| EPS (Basic) | (0.03) | (0.04) | (0.06) | (0.05) | (0.17) |
| EPS (Diluted) | (0.03) | (0.04) | (0.06) | (0.05) | (0.17) |
| Weighted Avg Shares | 252.46M | 269.84M | 278.56M | 281.08M | 287.21M |
| Weighted Avg Shares (Diluted) | 252.46M | 269.84M | 278.56M | 281.08M | 287.21M |
Spectral Medical Inc.
TSX:EDT.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.